531349 Stock Overview
Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceutical formulations and vaccines in India.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 531349 from our risk checks.
Panacea Biotec Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹139.25 |
| 52 Week High | ₹202.20 |
| 52 Week Low | ₹113.55 |
| Beta | 0.74 |
| 1 Month Change | 1.72% |
| 3 Month Change | -18.45% |
| 1 Year Change | 12.98% |
| 3 Year Change | -52.68% |
| 5 Year Change | -32.19% |
| Change since IPO | 374.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| 531349 | IN Biotechs | IN Market | |
|---|---|---|---|
| 7D | -4.6% | -5.0% | -2.1% |
| 1Y | 13.0% | 14.1% | 45.3% |
Return vs Industry: 531349 matched the Indian Biotechs industry which returned 13.4% over the past year.
Return vs Market: 531349 underperformed the Indian Market which returned 45% over the past year.
Price Volatility
| 531349 volatility | |
|---|---|
| 531349 Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 531349's share price has been volatile over the past 3 months.
Volatility Over Time: 531349's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,794 | Rajesh Jain | www.panaceabiotec.com |
Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceutical formulations and vaccines in India. It operates through Vaccines and Formulations segments. The company’s product portfolio includes prescription products in various therapeutic areas, such as pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, and gastro-intestinal care; and pneumococcal vaccine, dengue tetravalent vaccine, typhoid conjugate vaccine, and universal flu vaccine.
Panacea Biotec Limited Fundamentals Summary
| 531349 fundamental statistics | |
|---|---|
| Market cap | ₹8.51b |
| Earnings (TTM) | -₹116.77m |
| Revenue (TTM) | ₹5.52b |
1.5x
P/S Ratio-72.9x
P/E RatioIs 531349 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 531349 income statement (TTM) | |
|---|---|
| Revenue | ₹5.52b |
| Cost of Revenue | ₹2.38b |
| Gross Profit | ₹3.14b |
| Other Expenses | ₹3.25b |
| Earnings | -₹116.77m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.91 |
| Gross Margin | 56.88% |
| Net Profit Margin | -2.12% |
| Debt/Equity Ratio | 2.5% |
How did 531349 perform over the long term?
See historical performance and comparison